- Home
- HEPA vs PHIO Comparison
HEPA vs PHIO Comparison
Compare HEPA & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HEPA
- PHIO
- Stock Information
- Founded
- HEPA 2013
- PHIO 2011
- Country
- HEPA United States
- PHIO United States
- Employees
- HEPA N/A
- PHIO N/A
- Industry
- HEPA Biotechnology: Pharmaceutical Preparations
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- HEPA Health Care
- PHIO Health Care
- Exchange
- HEPA Nasdaq
- PHIO Nasdaq
- Market Cap
- HEPA 4.1M
- PHIO 3.4M
- IPO Year
- HEPA N/A
- PHIO N/A
- Fundamental
- Price
- HEPA $0.47
- PHIO $2.77
- Analyst Decision
- HEPA
- PHIO Strong Buy
- Analyst Count
- HEPA 0
- PHIO 1
- Target Price
- HEPA N/A
- PHIO $36.00
- AVG Volume (30 Days)
- HEPA 100.9K
- PHIO 18.5M
- Earning Date
- HEPA 11-14-2024
- PHIO 11-14-2024
- Dividend Yield
- HEPA N/A
- PHIO N/A
- EPS Growth
- HEPA N/A
- PHIO N/A
- EPS
- HEPA N/A
- PHIO N/A
- Revenue
- HEPA N/A
- PHIO N/A
- Revenue This Year
- HEPA N/A
- PHIO N/A
- Revenue Next Year
- HEPA N/A
- PHIO N/A
- P/E Ratio
- HEPA N/A
- PHIO N/A
- Revenue Growth
- HEPA N/A
- PHIO N/A
- 52 Week Low
- HEPA $0.43
- PHIO $1.53
- 52 Week High
- HEPA $3.49
- PHIO $10.35
- Technical
- Relative Strength Index (RSI)
- HEPA 42.44
- PHIO 50.99
- Support Level
- HEPA $0.43
- PHIO $2.41
- Resistance Level
- HEPA $0.53
- PHIO $4.53
- Average True Range (ATR)
- HEPA 0.07
- PHIO 0.83
- MACD
- HEPA -0.01
- PHIO 0.12
- Stochastic Oscillator
- HEPA 13.36
- PHIO 14.18
About HEPA Hepion Pharmaceuticals Inc.
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.